DE69738668D1 - Transgentier-modell für die krankheit von alzheimer - Google Patents

Transgentier-modell für die krankheit von alzheimer

Info

Publication number
DE69738668D1
DE69738668D1 DE69738668T DE69738668T DE69738668D1 DE 69738668 D1 DE69738668 D1 DE 69738668D1 DE 69738668 T DE69738668 T DE 69738668T DE 69738668 T DE69738668 T DE 69738668T DE 69738668 D1 DE69738668 D1 DE 69738668D1
Authority
DE
Germany
Prior art keywords
app
transgenic
pathology
human
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738668T
Other languages
English (en)
Inventor
Bernd Sommer
Matthias Staufenbiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9615569.2A external-priority patent/GB9615569D0/en
Priority claimed from GBGB9711262.7A external-priority patent/GB9711262D0/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE69738668D1 publication Critical patent/DE69738668D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69738668T 1996-07-24 1997-07-23 Transgentier-modell für die krankheit von alzheimer Expired - Lifetime DE69738668D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9615569.2A GB9615569D0 (en) 1996-07-24 1996-07-24 Improvements in or relating to organic compounds
GBGB9711262.7A GB9711262D0 (en) 1997-06-02 1997-06-02 Improvements in or relating to organic compounds
PCT/EP1997/003991 WO1998003644A1 (en) 1996-07-24 1997-07-23 Transgenic animal model for alzheimer disease

Publications (1)

Publication Number Publication Date
DE69738668D1 true DE69738668D1 (de) 2008-06-19

Family

ID=26309753

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738668T Expired - Lifetime DE69738668D1 (de) 1996-07-24 1997-07-23 Transgentier-modell für die krankheit von alzheimer

Country Status (8)

Country Link
EP (1) EP0920495B1 (de)
JP (2) JP2000515743A (de)
AT (1) ATE394481T1 (de)
AU (1) AU718473B2 (de)
DE (1) DE69738668D1 (de)
ES (1) ES2307300T3 (de)
PT (1) PT920495E (de)
WO (1) WO1998003644A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016951A1 (en) 1996-07-24 2001-08-23 Bernd Sommer Transgenic animal model for alzheimer disease
EP1063298A3 (de) * 1999-06-04 2001-03-28 Glaxo Group Limited Transgenes Tiermodell für die Krankheit von Alzheimer
GB0012056D0 (en) * 2000-05-18 2000-07-12 Consejo Superior Investigacion Model for neurodegenerative disease
CA2492930C (en) 2002-07-19 2013-01-08 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
SE0400707D0 (sv) 2004-03-22 2004-03-22 Bioarctic Neuroscience Ab Transgenic animal model
US7544855B2 (en) * 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
GB201204816D0 (en) 2012-03-19 2012-05-02 Brainco Biopharma S L Transgenic animal model of mood disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0620849B1 (de) * 1992-01-07 2003-06-25 Elan Pharmaceuticals, Inc. Transgene tiermodelle fur alzheimer-krankheit
WO1994012627A1 (en) * 1992-11-25 1994-06-09 Cephalon, Inc. Transgenic animal model for alzheimer's disease
DK0730643T3 (da) * 1993-10-27 2001-05-14 Elan Pharm Inc Transgene dyr, som huser APP-allel med svensk mutation

Also Published As

Publication number Publication date
JP2008054678A (ja) 2008-03-13
JP2000515743A (ja) 2000-11-28
AU3770797A (en) 1998-02-10
WO1998003644A1 (en) 1998-01-29
EP0920495B1 (de) 2008-05-07
EP0920495A1 (de) 1999-06-09
ES2307300T3 (es) 2008-11-16
JP4302158B2 (ja) 2009-07-22
ATE394481T1 (de) 2008-05-15
AU718473B2 (en) 2000-04-13
PT920495E (pt) 2008-08-18

Similar Documents

Publication Publication Date Title
ATE315085T1 (de) Transgene mäuse mit veränderter apolipoprotein e- expression und testverfahren.
Orth et al. Stream habitat management
DE69133372D1 (de) Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
DE69920425D1 (de) Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter
Tobias et al. Vocal communication between male Xenopus laevis
CA2268812A1 (en) Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
PL323109A1 (en) Genetic sequences and proteins associated with alzheimer disease and their application
ES2179512T3 (es) Pez transgenico con expresion tisular especifica.
DE69738668D1 (de) Transgentier-modell für die krankheit von alzheimer
ATE541923T1 (de) Transgener c. elegans als modellorganismus für untersuchungen zur alzheimer'schen krankheit
Miskin et al. αMUPA mice: a transgenic model for longevity induced by caloric restriction
WO2002016417A3 (en) Transgenic animal model for neurodegerative disease and uses thereof
WO1998001549A3 (en) Genetic sequences and proteins related to alzheimer's disease, and uses therefor
WO2001091548A3 (en) Mice heterozygous for wfs1 gene as mouse models for depression
ATE396263T1 (de) Transgenes tiermodel für neurodegenerative erkrankungen
ATE499832T1 (de) Transgenes tiermodel für neurodegenerative krankheiten
ATE336888T1 (de) Caspase 1 transgenes tier
EP1373525A4 (de) Gen-targeting-tiermodell für die wechselwirkung der apolipoprotein e4-domäne und verwendungen davon
WO1998003643A3 (en) Transgenic animals with mutant human APP or A4CT sequences
DE60044205D1 (de) Transgenes tier welches ein mehrfach-mutiertes presenilin-1 exprimiert
WO2004063354A3 (en) Compositions and methods for characterizing and regulating wnt pathways
WO1998002036A3 (en) Animal model knock-out for a neuronal intermediate filament protein
Koo et al. Identification of an enhancer region in the mouse ephA8 locus directing expression to the anterior region of the dorsal mesencephalon
KR101076837B1 (ko) 방사능 수치 측정 센서가 장착된 휴대용 기기에서의 사이버 생물 육성 장치 및 방법과 그 시스템
RU2006114692A (ru) Трансгенные животные, имеющие основные расстройства, связанные с болезнью альцгеймера

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN